lymphoma

[Blood Advances] Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase I/II study in patients with various B-cell malignancies. Zanubrutinib was well tolerated and demonstrated activity in patients with relapsed/refractory mantle cell lymphoma.

[Blood] Scientists performed an extensive medicinal chemistry campaign and identified KIN-8194 as a novel dual inhibitor of HCK and BTK. KIN-8194 showed potent and selective in vitro killing of MYD88 mutated lymphoma cells, including ibrutinib resistant BTKCys481Ser expressing cells.

[Bristol Myers Squibb] Bristol Myers Squibb announced positive results from TRANSFORM, a Phase III study evaluating Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma compared to salvage therapy followed by high-dose chemotherapy and hematopoietic stem cell transplant.

[AbbVie, Inc.] AbbVie, Inc. announced new data from the Phase III GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® plus VENCLEXTA®/VENCLYXTO® versus chlorambucil plus obinutuzumab for first-line treatment in patients with CLL or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria.

[Journal of Clinical Oncology] This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in newly diagnosed patients with acute myeloid leukemia (AML) and relapsed or refractory AML.

[Aging-Us] Scientists explored the anti-cancer activity of Antrodia salmonea (AS) in colon cancer cells.MTT assay revealed that AS showed a remarkable effect on cell viability in colon cancer cells